ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3132

Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors

Pei-Suen Tsou1,2, M. Asif Amin3, Elena Schiopu2,4, David A. Fox3, Dinesh Khanna1,2 and Amr H. Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan Scleroderma Program, Ann Arbor, MI, 3Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Angiogenesis, epigenetics and histone acetylation, Scleredema

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Scleroderma (SSc) is a complex disease characterized by inflammation, vascular complications, and excessive deposition of extracellular matrix. Vascular dysfunction represents a disease initiating event in SSc. Indeed, endothelial cell (EC) damage is thought to trigger a self-fueling process that results in tissue fibrosis. Recent data suggest that epigenetic dysregulation impairs normal angiogenesis and can result in abnormal blood vessel growth patterns in various disease conditions. Studies have shown that histone deacetylases (HDACs) control EC proliferation and participate in EC migration. Specifically, HDAC5 appears to be anti-angiogenic through the repression of pro-angiogenic factors such as basic fibroblasts growth factors (bFGF), vascular endothelial growth factor (VEGF), and epherin B2. The phenotypic and functional abnormalities of SSc ECs are stable in vitroover multiple generations of tissue culture, suggesting that persistent epigenetic changes might play a role in EC dysfunction in SSc. We hypothesized that HDAC5 contributes to impaired angiogenesis in SSc by repressing pro-angiogenic factors in ECs.  

Methods:

Dermal ECs were isolated from biopsies from patients with diffuse cutaneous SSc. HDAC5, VEGF, and ephrin B2 expression were determined by qPCR. HDAC5 was knocked down using HDAC5 siRNA. Angiogenesis was assessed by an in vitroMatrigel tube formation assay. bFGF and VEGF in culture media were measured using ELISA. A paired t-test was used to compare differences between groups, and a p-value of <0.05 was considered significant. An assay for transposase-accessible chromatin using sequencing (ATAC-seq) was performed to assess and localize genome-wide effects of HDAC5 knockdown on chromatin accessibility. 

Results:

The expression of HDAC5 was significantly increased in SSc ECs compared to normal ECs (0.0058 ± 0.0017 vs. 0.0028 ± 0.0003, p<0.05) while pro-angiogenic ephrin B2 was down regulated (0.0021 ± 0.0011 vs. 0.0096 ± 0.0005, p<0.05). Cells transfected with HDAC5 siRNA showed 87% knockdown in SSc ECs. Silencing of HDAC5 in SSc ECs restored normal angiogenesis, as reflected by a significant increase in tube formation on Matrigel compared to sham-transfected cells. After HDAC5 knockdown, ephrin B2 mRNA decreased 50% compared to sham-transfected group in SSc ECs. In contrast, SSc ECs released increased amounts of VEGF and bFGF into the cell culture media (2 and 1.2 fold for VEGF and bFGF). In addition, VEGF mRNA increased significantly after HDAC5 knockdown (2.9 fold, p<0.05). ATAC-seq was used to identify additional HDAC5-regulated targets in EC, which will help to further mechanistically understand the anti-angiogenic effects of HDAC5. 

Conclusion:

By knocking down HDAC5 in SSc ECs, we were able to restore the tube-forming ability of these cells. Our data indicate that overexpression of HDAC5 in SSc gears ECs to an anti-angiogenic state via repressing pro-angiogenic factors such as VEGF and bFGF. This appears to be a complicated process, as HDAC5 knockdown decreased pro-angiogenic ephrin B2. We provided a link between epigenetic regulation and impaired angiogenesis in SSc, and present a novel mechanism for the dysregulated angiogenesis that characterizes this disease.


Disclosure: P. S. Tsou, None; M. A. Amin, None; E. Schiopu, None; D. A. Fox, None; D. Khanna, Bristol-Myers Squibb, 2,EMD Serono, 2,Genentech and Biogen IDEC Inc., 2,Bayer, 5,Biogen Idec, 5,Cytori, 5,EMD Serono, 5,Forward, 5,Genentech and Biogen IDEC Inc., 5,Gilead, 5,Lycera, 5,Seattle Genetics, 5; A. H. Sawalha, None.

To cite this abstract in AMA style:

Tsou PS, Amin MA, Schiopu E, Fox DA, Khanna D, Sawalha AH. Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/histone-deacetylase-5-is-overexpressed-in-scleroderma-endothelial-cells-and-impairs-angiogenesis-via-repressing-pro-angiogenic-factors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histone-deacetylase-5-is-overexpressed-in-scleroderma-endothelial-cells-and-impairs-angiogenesis-via-repressing-pro-angiogenic-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology